Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00280-008-0730-xPMID 18398615
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study

  2008influential reference
• Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations

  2006cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors

  2006cited by this paper
• Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

  2005influential reference
• Clinical Pharmacokinetics of Imatinib

  2005influential reference
• METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

  2005influential reference
• Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

  2005influential reference
• Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates

  2004cited by this paper
• Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588

  2004cited by this paper
• Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

  2004cited by this paper
• Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004cited by this paper
• Biliary Excretion of Imatinib Mesylate and Its Metabolite CGP 74588 in Humans

  2004cited by this paper
• Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion

  2004cited by this paper
• FDA approves Gleevec for pediatric leukemia.

  2003cited by this paper
• High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.

  2002cited by this paper
• Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

  2002cited by this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cited by this paper
• Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.

  2002cited by this paper
• Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check

  2001cited by this paper
• Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.

  2001cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000cited by this paper
• Platelet-Derived Growth Factor-AA and -α Receptor Expression Suggests an Autocrine and/or Paracrine Loop in Osteosarcoma

  2000cited by this paper
• Effects of human platelet-derived growth factor-AB on sarcoma growth in vitro and in vivo.

  1999cited by this paper
• Cytochrome P450 3A

  1999cited by this paper
• The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.

  1997cited by this paper
• Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans

  1996cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996cited by this paper

• Novel phenylamino pyrimidine derivatives as potent and selective inhibitors of ABL1 tyrosine kinase for targeted anticancer therapy.

  2026cites this paper
• Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting

  2025influential citation
• Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients

  2025influential citation
• A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients

  2024cites this paper
• Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling

  2024cites this paper
• Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?

  2024cites this paper
• Clinical pharmacokinetics and Drug-drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: a clinical perspective.

  2024cites this paper
• Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients

  2024cites this paper
• Are novel oral oncolytics underdosed in obese patients?

  2023cites this paper
• Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19

  2023cites this paper
• Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis

  2023cites this paper
• Gene polymorphisms affect postoperative imatinib plasma levels and edema in adults with gastrointestinal stromal tumor.

  2023cites this paper
• Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation

  2023cites this paper
• Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: Relationship between covariates and imatinib plasma trough level

  2023cites this paper
• Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia

  2023cites this paper
• Validation of an LC-MS/MS assay for rapid and simultaneous quantification of 21 kinase inhibitors in human plasma and serum for therapeutic drug monitoring.

  2023cites this paper
• Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg

  2022cites this paper
• Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia

  2022cites this paper
• Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

  2022cites this paper
• External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia

  2021cites this paper
• Chronic Myeloid Leukaemia with Priapism….A Rare Finding

  2020cites this paper
• Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

  2020cites this paper
• Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.

  2020cites this paper
• Adolescent and Young Adult Chronic Myeloid Leukemia in Real-World Settings: Experience from a Tertiary Care Institute in Northern India

  2019cites this paper
• Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia

  2019cites this paper
• Imatinib, sunitinib and pazopanib: From flat‐fixed dosing towards a pharmacokinetically guided personalized dose

  2019cites this paper
• Population pharmacokinetic and pharmacogenetics of imatinib in Chinese patients with chronic myeloid leukemia.

  2019cites this paper
• Toward a more individualised treatment of patients with gastrointestinal stromal tumour

  2018cites this paper
• Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial

  2018cites this paper
• Pharmacology and pharmacokinetics of imatinib in pediatric patients

  2018influential citation
• Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.

  2017cites this paper
• Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs

  2017cites this paper
• Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance

  2017cites this paper
• Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers

  2016cites this paper
• Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour

  2016cites this paper
• Population pharmacokinetics of imatinib mesylate in healthy Korean subjects

  2016cites this paper
• Detailed study of imatinib metabolization using high-resolution mass spectrometry.

  2015cites this paper
• Individualized dosing of tyrosine kinase inhibitors: are we there yet?

  2015cites this paper
• Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia

  2015cites this paper
• Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity

  2015cites this paper
• Clinical Pharmacology in Pediatrics

  2014cites this paper
• Pharmacokinetics, Microbial Response, and Pulmonary Outcomes of Multidose Intravenous Azithromycin in Preterm Infants at Risk for Ureaplasma Respiratory Colonization

  2014cites this paper
• Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.

  2014cites this paper
• Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia

  2014cites this paper
• Optimizing drug development of anti‐cancer drugs in children using modelling and simulation

  2013cites this paper
• Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.

  2013cites this paper
• Systematic Review of Population Pharmacokinetic Analyses of Imatinib and Relationships With Treatment Outcomes

  2013cites this paper
• Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors

  2013cites this paper
• Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma.

  2013cites this paper
• Monitoring disease response in chronic-phase chronic myeloid leukemia: the age of molecular assays?

  2012cites this paper
• Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure

  2012cites this paper
• Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy

  2012cites this paper
• Therapeutic Drug Monitoring of Imatinib

  2012cites this paper
• Evaluation de différents descripteurs de poids chez le sujet obèse à l’aide d’un modèle de pharmacocinétique de population - application à la metformine, la morphine et l’imatinib

  2012cites this paper
• The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid

  2012cites this paper
• Potentiometric Determination of Imatinib under Batch and Flow Injection Analysis Conditions

  2012cites this paper
• Mathematical model development to investigate the pharmacokinetic variability of two anticancer drugs

  2012cites this paper
• Isoniazid The Pharmacogenetics of NAT 2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving

  2011cites this paper
• Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems

  2011cites this paper
• Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

  2011cites this paper
• Targeted therapy in pediatric and adolescent oncology

  2011cites this paper
• Association of Genetic Polymorphisms in the Influx Transporter SLCO1B3 and the Efflux Transporter ABCB1 With Imatinib Pharmacokinetics in Patients With Chronic Myeloid Leukemia

  2011cites this paper
• transporter SLCO1B3 and the efflux transporter AB

  2011cites this paper
• Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

  2010cites this paper
• Imatinib

  2010cites this paper
• Niveau de preuve du suivi thérapeutique pharmacologique des inhibiteurs de tyrosine-kinase dans le traitement des leucémies myéloïdes chroniques.

  2010cites this paper
• Imatinib mesylate in children and adolescents with cancer

  2010cites this paper
• [Not Available].

  2010cites this paper
• Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.

  2010cites this paper
• Clinical pharmacology in the adolescent oncology patient.

  2010cites this paper
• Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?

  2009cites this paper
• Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

  2009cites this paper
• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  2009cites this paper
• Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.

  2009cites this paper
• Imatinib Mesylate Pharmacokinetics Before and After Sleeve Gastrectomy in a Morbidly Obese Patient with Chronic Myeloid Leukemia

  2009cites this paper
• Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

  2008cites this paper